Key terms

About KROS

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest KROS news

Apr 04 12:10pm ET Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call by TipRanks Mar 29 3:05am ET Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012 by TipRanks Mar 19 8:04am ET Morphic appoints Cooper as Chief Medical Officer by TipRanks Mar 19 1:37am ET Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment by TipRanks Mar 13 7:35am ET Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS) by TipRanks Mar 13 5:39am ET Keros Therapeutics initiated with a Not Rated at Goldman Sachs by TipRanks Mar 06 8:12am ET Keros Therapeutics Updates Corporate Presentation Online by TipRanks Mar 06 8:06am ET Keros Therapeutics (KROS) Gets a Buy from Truist Financial by TipRanks Mar 05 8:12am ET Keros Therapeutics CMO Simon Cooper Resigns by TipRanks Mar 05 8:12am ET Keros Therapeutics CEO to Speak at Global Biopharma Conference by TipRanks Mar 01 7:06am ET Analysts’ Top Healthcare Picks: Xenon (XENE), Ascendis Pharma (ASND) by TipRanks Mar 01 6:20am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR) by TipRanks Mar 01 12:57am ET Buy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic Catalysts by TipRanks Feb 29 10:55am ET Optimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy Rating by TipRanks Feb 29 6:48am ET Buy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial Position by TipRanks Feb 29 6:20am ET Keros Therapeutics price target raised to $77 from $60 at Wells Fargo by TipRanks Feb 28 4:12pm ET Keros Therapeutics reports Q4 EPS ($1.34) , consensus ($1.37) by TipRanks Feb 26 11:45am ET Truist biotech analysts hold an analyst/industry conference call by TipRanks Feb 26 4:55am ET Truist biotech analysts hold an analyst/industry conference call by TipRanks Feb 21 12:10pm ET Truist biotech analysts hold an analyst/industry conference call by TipRanks Feb 21 7:12am ET Keros Therapeutics initiated with an Outperform at William Blair by TipRanks Jan 23 8:15am ET Jefferies Analyst Issues Buy Rating for Keros Therapeutics, Citing Strong Pipeline and Financial Stability by TipRanks Jan 09 7:37am ET Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS) by TipRanks

No recent press releases are available for KROS

KROS Financials

1-year income & revenue

Key terms

KROS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

KROS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching